Effect of azithromycin combined with montelukast on children with mycoplasma pneumoniae pneumonia and its effects on T lymphocyte subsets, immunoglobulin, complement C3 and C4 in children

Abstract

Objective To observe the efficacy of azithromycin combined with montelukast in the treatment of children with mycoplasma pneumoniae pneumonia and its effects on T lymphocyte subsets, immunoglobulin, complement C3 and C4 in children. Methods Four hundred cases of mycoplasma pneumoniae pneumonia were selected. The children were divided into the control group and the observation group by the random digital table, with 200 cases in each group. The control group was treated with azithromycin sequential therapy, and the observation group was treated with azithromycin sequential therapy combined with montelukast sodium. The total clinical effective rate, the time of clinical symptoms and signs disappearance, the changes of T lymphocyte subsets, immunoglobulin, complement C3 and C4 before and after treatment were compared between the two groups. Results The total clinical efficiency in observation group(94.5%)after treatment was significantly higher than that of control group (77%) (P 0.05). No serious adverse reactions were found in the two groups. Conclusions Azithromycin combined with montelukast can dramatically improve the treatment of mycoplasma pneumoniae pneumonia in children, and is safe, effective. Observing the T lymphocyte subsets, immunoglobulin, and complement C3 and C4 changes in the peripheral blood is worthy of clinical application. Key words: Mycoplasma pneumoniae pneumonia; Children; Azithromycin; Montelukast sodium; Immunoglobulins; T lymphocyte subsets; Complement 3; Complement 4